RE:Stock Price Lots of questions, in there last management discussion they commented that the cash on hand is expected to support the operations into the first quarter of 2021. The Company has slowed down development efforts to conserve cash until additional financing is obtained.
Tha alzehimers blood-based testing announced in February with the Toronto Memory Clinic was supposed to be for a period of 6 months, should be over. The Covid Serology tesing according to one of Elliot's podcast should have been wrapping up by the end of the third quarter. They talked about purchasing equipment in August?, in September update PMN310 will utilize blood-based biomarkers in initial trials, enabling rapid timeframe and limited capital needs to value-creating data.
I think soon we will know if there is anything value in this science.